Abstract
Headquartered in Japan, Eisai operates in two main business areas:
Pharmaceuticals, including ethical drugs, OTC products and diagnostics; and
Others, which comprises pharmaceutical production systems and equipment. Eisai
has clinical research bases in North America, Europe, Asia and Japan, and
employs over 10,600 people worldwide. Eisai sells prescription products within
the following therapeutic areas: neurology; gastroenterology; metabolic;
anti-inflammatory; diagnostics and oncology. It is now focusing its research
and development efforts on neurology, gastroenterology and oncology/critical
care.
Recent shifts in the Japanese economic environment have increased competition
for domestic pharmaceuticals as the larger pharma companies from Europe and
the US are afforded more and more of the Japanese market share. Consequently,
many of the smaller Japanese pharmaceuticals have struggled, leading them to
pursue mergers, of which there were three notable examples in 2005 (Daiichi
Sankyo, Astellas Pharma and Dainippon Sumitomo), and two more announced in
2007 (Mitsubishi Tanabe Pharma and Kyowa Hakko Kirin).
Eisai has been one of the exceptions, largely due to its long-established
global operations. Foreign subsidiaries and operations generated 57.5 per cent
of Eisai' s sales in fiscal 2009 (compared to 52.6 per cent in fiscal 2006),
and the company continues to strive to create efficient global management.
Much of Eisai' s globalisation has been generated through the success of its
two core products: Aricept, for the treatment of Alzheimer' s disease, and
Aciphex/Pariet, a therapy for gastric acid-related conditions. In order to
maximise the value of these products abroad, Eisai recognised the need for
strategic alliances with companies with greater experience in foreign markets.
Therefore, Eisai has been marketing Aricept in various markets with the
pharmaceutical giant Pfizer since November 1994, and Aciphex/Pariet has
benefited from co-marketing with Janssen Pharmaceutica (a major subsidiary of
Johnson & Johnson) in both European and US markets since January 1997. Such is
Eisai' s confidence in the recognition and standing of these products, and in
its own US operations, the company assumed total control over the marketing of
Aricept in the US in September 2005, and of Aciphex/Pariet, earlier in January
2004. Eisai is now targeting the emerging markets of China and India and, in
October 2004, established the first Japanese pharmaceutical subsidiary in
India, followed in March 2007, by the establishment of an active
pharmaceutical ingredient R&D and manufacturing subsidiary, Eisai
Pharmatechnology Manufacturing Pvt Ltd in Vishakhapatnam, which will commence
operations in fiscal 2010. Eisai will be committing resources to these markets
on a priority basis, thus laying the foundations for future business.
Both of the aforementioned products will be the key growth drivers for Eisai
in the short-term, however, pending patent expirations (25th November 2010,
for Aricept, and May 2013, for Aciphex/Pariet) are a serious concern for the
company which will need to be addressed. Eisai has responded by targeting a
new therapeutic of interest, oncology and critical care. Eisai believes this
field has significant levels of unmet needs and therefore, the potential to
generate growth in the long-term. Eisai' s confidence and dedication to this
strategy has been demonstrated by its recent acquisitions of Morphotek and MGI
Pharma, two biopharmaceutical companies with extensive history in the field of
oncology. Eisai has also purchased rights to five oncology products from
Ligand Pharmaceuticals.
This new strategic analysis report Eisai: Pipeline - Products - Performance
- Potential, provides a complete and critical review of the company and
includes unique and independent assessments and forecasts of key products.
Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Geographic Strategy
- Production
- Employees
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- NEUROLOGY
- Marketed Products
- Aricept
- Inovelon
- Methycobal/Nabolin S
- Neurobloc
- Other Neurology products
- Lusedra
- R&D Projects
- E2012
- E2508
- E6201
- Eszopiclone
- Permapanel
- Ranirestat
- Zebinix
- Growth Forecast
- GAS TROENTEROLOGY
- Marketed Products
- Aciphex/Pariet
- Selbex
- Others
- R&D Projects
- Growth Forecast
- METABOLIC
- Marketed Products
- R&D Projects
- Glufast
- SA-001
- Sibutramine
- Growth Forecast
- ANTI-INFLAMMATORY
- Marketed Products
- R&D Projects
- E6007
- E6201
- Iguratimod
- Saforis
- Growth Forecast
- DIA GNOSTICS
- Marketed Products
- Growth Forecast
- ONCOLOGY
- Marketed Products
- Others
- R&D Projects
- AKR-201
- Amolimogene
- Bendamustine
- E6201
- E7080
- E7107
- E7820
- E7974
- Eribulin
- Farletuzumab
- Indislam
- Irofulven
- MORAb-009
- ZYC300
- Growth Forecast
- OTHERS
- R&D Projects
- AKR-501
- E1224
- E5555
- Eritoran
- APPENDIX 1 - FINANCIA L PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Abbott
- Ajinomoto/sanofi-aventis
- AkaRX Inc
- Asahi Kasei Pharma Corporation
- Bial-Portela & C SA
- BioArctic Neuroscience AB
- Biocompatibles
- Bukwang Pharm
- Cancer Innovations (CI)
- CMC Biopharmaceuticals
- Dainippon Sumitomo Pharma
- DNAVEC Corporation
- Elan Corporation plc
- GlaxoSmithKline
- Helsinn Healthcare SA
- Human Genome Sciences (HGS)
- Johnson & Johnson
- Kissei Pharmaceuticals
- Lion Corporation
- Lonza
- Ludwig Institute for Cancer Research
- Minophagen Pharmaceutical Co Ltd
- M' s Science Corporation
- MultiCell Technologies Inc
- National Cancer Institute
- Novartis
- Pfizer
- Radius Health Inc
- Salix Pharmaceuticals Inc
- Sepracor Inc
- Solstice Neurosciences Inc
- Solvay
- Symbio Pharmaceuticals Ltd
- Synageva BioPharma
- Teikoku Seiyaku Co Ltd
- TorreyPines Therapeutics Inc
- Toyama Chemical Co Ltd
- University Hospital Heidelberg
- University of Pennsylvania
- Others
- APPENDIX 4 - INFRAS TRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - MAJOR PHARMACEUTICAL
- SUBSI DIA RIES/JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income (Loss) By Business Area
- Total Assets By Business Area
- Sales By Destination
- Sales By Origin
- Operating Income (Loss) By Geographical Area
- Total Assets By Geographical Area
- Employees By Geographical Location
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Neurology Products, 2009
- Major Gastroenterology Products, 2009
- Major Anti-Inflammatory Products, 2009
- Major Diagnostic Products, 2009
- Major Domestic Subsidiaries
- Major North American Subsidiaries
- Major European Subsidiaries
- Major Asian Subsidiaries
INDEX OF CHARTS
- Sales, Costs and Operating Income
- R&D Expenditure and Capital Expenditure
- Sales By Business Area
- Operating Income (Loss) By Business Area
- Sales By Destination, 2009
- Sales By Origin
- Operating Income (Loss) By Geographical Area
- Employees By Geographic Segment, 2009
- Sales of Current Major Products (2004A-2014E)
- Sales of Major Products, 2009
- Aricept Sales (2004A-2014E)
- Inovelon Sales (2009E-2014E)
- Methycobal Sales (2004A-2014E)
- NeuroBloc Sales (2009E-2014E)
- Perampanel Sales (2008E-2014E)
- Ranirestat Sales (2009E-2014E)
- Aciphex/Pariet Sales (2004A-2014E)
- Selbex Sales (2004A-2014E)
- Gasmotin Sales (2009E-2014E)
- Major Metabolic Products, 2009
- Sibutramine Sales (2009E-2014E)
- Actonel Sales (2006A-2014E)
- Humira Sales (2009E-2014E)
- Dacogen Sales (2009E-2014E)
- Eritoran Sales (2011E-2015E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
